The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

ImmunityBio, Inc.’s IBRX share price has dipped by 6.65%, which has investors questioning if this is right time to buy.

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look ...

CULVER CITY, Calif., April 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for ...

IBRX is a clinical-stage biotech company developing immune-enhancing therapies for cancer and infectious diseases. It is underway with its global expansion for its novel immunotherapy ANKTIVA ...

The latest analyst rating for ImmunityBio (NASDAQ:IBRX) was provided by HC Wainwright & Co., and ImmunityBio reiterated their buy rating. The last downgrade for ImmunityBio Inc happened on May 12 ...

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for ...

In terms of financial performance, ImmunityBio reported that its Q1 2025 Anktiva unit sales volume grew by 150% over the unit ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.